Rezultaty - David M. Pariser
- Rezultaty 1 - 20 Rezultaty od 33
- Idź do następnej strony
-
1
-
2
-
3
-
4
-
5
Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States od Alexa B. Kimball, Jennifer Schenfeld, Neil A. Accortt, Mary S. Anthony, Kenneth J. Rothman, David M. Pariser
Wydane 2015Artigo -
6
-
7
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety... od Robert Bissonnette, David M. Pariser, Norman Wasel, Joana Gonçalves, Robert M. Day, Rongdean Chen, Michael Sebastian
Wydane 2016Artigo -
8
Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follo... od Eduardo Tschen, David S.Y. Wong, David M. Pariser, F E DUNLAP, Anna Houlihan, Mary Beth Ferdon
Wydane 2006Artigo -
9
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patient... od Kim Papp, David M. Pariser, Mary Catlin, G. Wierz, Greg Ball, B. Akinlade, Bernhardt Zeiher, James G. Krueger
Wydane 2015Artigo -
10
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis od Amy S. Paller, Elaine C. Siegfried, David M. Pariser, Kara Rice, Mona Trivedi, Jan Iles, David H. Collier, Greg Kricorian, Richard Langley
Wydane 2016Artigo -
11
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials od Linda Stein Gold, Mark Lebwohl, Jeremy Sugarman, David M. Pariser, Tina Lin, Gina Martin, Radhakrishnan Pillai, Robert J. Israel, Tage Ramakrishna
Wydane 2018Artigo -
12
Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials od Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast, William Philip Werschler, Lawrence Green, Richard D. Mamelok, Janice Drew, John Quiring, David M. Pariser
Wydane 2018Artigo -
13
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial od Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, Elena Peeva
Wydane 2020Artigo -
14
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis od Amy S. Paller, Elaine C. Siegfried, Richard Langley, Alice B. Gottlieb, David M. Pariser, Ian Landells, Adelaide A. Hebert, Lawrence F. Eichenfield, Vaishali Patel, Kara Creamer, Angelika Jahreis
Wydane 2008Artigo -
15
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies od Mark Boguniewicz, Andrew Alexis, Lisa A. Beck, Julie Block, Lawrence F. Eichenfield, Luz Fonacier, Emma Guttman‐Yassky, Amy S. Paller, David M. Pariser, Jonathan I. Silverberg, Mark Lebwohl
Wydane 2017Revisão -
16
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis od Eric L. Simpson, Laurent Eckert, Abhijit Gadkari, Usha G. Mallya, Min Yang, Lauren Nelson, T. Michelle Brown, Matt Reaney, Puneet Mahajan, Isabelle Guillemin, Mark Boguniewicz, David M. Pariser
Wydane 2019Artigo -
17
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis od Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott D. Glazer, Naji Tawfik, Patricia A. Walicke, Wolfgang Dummer, Xiaolin Wang, Marvin R. Garovoy, David M. Pariser
Wydane 2003Artigo -
18
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) od David M. Pariser, Eric L. Simpson, Abhijit Gadkari, Thomas Bieber, David J. Margolis, T. Michelle Brown, Lauren Nelson, Puneet Mahajan, Matthew Reaney, Isabelle Guillemin, Usha G. Mallya, Laurent Eckert
Wydane 2019Artigo -
19
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the op... od Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball
Wydane 2023Artigo -
20
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results od Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Girish Aras, Neil A. Accortt, Michele Hooper, Kara Rice, Joel M. Gelfand
Wydane 2014Artigo
Narzędzie wyszukiwania:
Podobne hasła
Medicine
Dermatology
Internal medicine
Psoriasis
Randomized controlled trial
Adverse effect
Pathology
Surgery
Alternative medicine
Clinical endpoint
Placebo
Clinical trial
Pharmacology
Plaque psoriasis
Atopic dermatitis
Disease
Etanercept
Psoriasis Area and Severity Index
Computer science
Discontinuation
Gastroenterology
Intensive care medicine
Nursing
Quality of life (healthcare)
Adalimumab
Biology
Body surface area
Cancer
Chemistry
Confidence interval